T cell-mediated immunity towards yellow fever virus and useful animal models

Viruses

Volumn 9, Issue 4, 2017, Pages

  Watson, Alan M ^a   Klimstra, William B ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

17D; 17D 204; 17DD; Animal models; Chimerivax; Dengue; Flavivirus; Live attenuated vaccine; T cell; Vaccine; Vaccine development; West Nile; Yellow fever virus; YFV; Zika

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ANIMAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENDEMIC DISEASE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION RISK; INNATE IMMUNITY; NONHUMAN; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS TRANSMISSION; YELLOW FEVER; YELLOW FEVER VIRUS; ANIMAL; DISEASE MODEL; IMMUNOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; T-LYMPHOCYTES; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 85017656955     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9040077     Document Type: Review

References (84)

1. Monath, T.P., Gershman, M., Erin Staples, J., Barrett, A.D.T. Yellow fever vaccine. In Vaccines; Plotkin, S.A., Orenstein, W.A., Offit, P.A., Eds., Saunders Elsevier: London, UK, 2012; pp. 870–968.
2. Bryant, J.E., Holmes, E.C., Barrett, A.D.T. Out of Africa: A molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog. 2007, 3, e75.
3. Reed, W., Carroll, J., Agramonte, A., Lazear, J.W. The etiology of yellow fever—A preliminary note. Public Health Pap. Rep. 1900, 26, 37–53.
4. Stokes, A., Bauert, J.H., Hudson, N.P. Experimental transmission of yellow fever virus to laboratory animals. Int. J. Infect. Dis. 1997, 2, 54–59.
5. Stokes, A., Bauer, J.H., Hudson, N.P. The Transmission of yellow fever to Macacus rhesus: Preliminary note. J. Am. Med. Assoc. 1928, 90, 253.
6. Theiler, M. Studies on the action of yellow fever virus in mice. Ann. Trop. Med. Parasitol. 1930, 24, 249–272.
7. Sellards, A.W. The behavior of the virus of yellow fever in monkeys and mice. PNAS 1931, 17, 339–343.
8. Theiler, M., Smith, H.H. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J. Exp. Med. 1937, 65, 767–786.
9. Theiler, M., Smith, H.H. The Use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 65, 787–800.
10. Norrby, E. Yellow fever and Max Theiler: The only Nobel Prize for a virus vaccine. J. Exp. Med. 2007, 204, 2779–2784.
11. Frierson, J.G. The yellow fever vaccine: A history. Yale J. Biol. Med. 2010, 83, 77–85.
12. World Health Organization, Division of Epidemiological Surveillance and Health Situation Trend Assessment. Global Health Situation and Projections—Estimates; World Health Organization: Geneva, Switzerland, 1992.
13. Li, R., Ding, J., Li, H. Six cases of imported yellow fever in China: 12 March 2016–24 March 2016. Radiol. Infect. Dis. 2016, 3, 143–144.
14. Wasserman, S., Tambyah, P.A., Lim, P.L. Yellow fever cases in Asia: Primed for an epidemic. Int. J. Infect. Dis. 2016, 48, 98–103.
15. Monaghan, A.J., Morin, C.W., Steinhoff, D.F., Wilhelmi, O., Hayden, M., Quattrochi, D.A., Reiskind, M., Lloyd, A.L., Smith, K., Schmidt, C.A., et al. On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States. PLoS Curr. 2016, doi:10.1371/currents.outbreaks.50dfc7f46798675fc63e7d7da563da76.
16. Bredenbeek, P.J., Kooi, E.A., Lindenbach, B., Huijkman, N., Rice, C.M., Spaan, W.J.M. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in Flavivirus replication. J. Gen. Virol. 2003, 84, 1261–1268.
17. Tao, D., Barba-Spaeth, G., Rai, U., Nussenzweig, V., Rice, C.M., Nussenzweig, R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: Protection in a rodent malaria model. J. Exp. Med. 2005, 201, 201–209.
18. Bredenbeek, P.J., Molenkamp, R., Spaan, W.J.M., Deubel, V., Marianneau, P., Salvato, M.S., Moshkoff, D., Zapata, J., Tikhonov, I., Patterson, J., et al. A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345, 299–304.
19. Franco, D., Li, W., Qing, F., Stoyanov, C.T., Moran, T., Rice, C.M., Ho, D.D. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine 2010, 28, 5676–5685.
20. Stoyanov, C.T., Boscardin, S.B., Deroubaix, S., Barba-Spaeth, G., Franco, D., Nussenzweig, R.S., Nussenzweig, M., Rice, C.M. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 2010, 28, 4644–4652.
21. Nogueira, R.T., Nogueira, A.R., Pereira, M.C.S., Rodrigues, M.M., Neves, P.C.D.C., Galler, R., Bonaldo, M.C. Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS ONE 2013, 8, e59347.
22. Monath, T.P., Soike, K., Levenbook, I., Zhang, Z.-X., Arroyo, J., Delagrave, S., Myers, G., Barrett, A.D.T., Shope, R.E., Ratterree, M., et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVaxTM) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999, 17, 1869–1882.
23. Pulendran, B. Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 2009, 9, 741–747.
24. Thomas, R.E., Lorenzetti, D.L., Spragins, W., Jackson, D., Williamson, T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine 2011, 29, 4544–4555.
25. Hayes, E.B. Is it time for a new yellow fever vaccine? Vaccine 2010, 28, 8073–8076.
26. Belsher, J.L., Gay, P., Brinton, M., DellaValla, J., Ridenour, R., Lanciotti, R., Perelygin, A., Zaki, S., Paddock, C., Querec, T., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25, 8480–8485.
27. Pulendran, B., Miller, J., Querec, T.D., Akondy, R., Moseley, N., Laur, O., Glidewell, J., Monson, N., Zhu, T., Zhu, H., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 2008, 198, 500–507.
28. Theiler, M., Sellards, A.W., Sellards, A.W. The immunological relationship of yellow fever as it occurs in West Africa and in South America. Ann. Trop. Med. Parasitol. 1928, 22, 449–460.
29. Gotuzzo, E., Yactayo, S., Cordova, E. Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years. Am. J. Trop. Med. Hyg. 2013, 89, 434–444.
30. Reinhardt, B., Jaspert, R., Niedrig, M., Kostner, C., L’age-Stehr, J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human Flavivirus infection. J. Med. Virol. 1998, 56, 159–167.
31. Niedrig, M., Lademann, M., Emmerich, P., Lafrenz, M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: Neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health 1999, 4, 867–871.
32. Poland, J.D., Calisher, C.H., Monath, T.P., Downs, W.G., Murphy, K. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. 1981, 59, 895–900.
33. Wieten, R.W., Jonker, E.F.F., Leeuwen, E.M.M.V., Remmerswaal, E.B.M., Berge, I.J.M.T., Visser, A.W.D., Genderen, P.J.J.V., Goorhuis, A., Visser, L.G., Grobusch, M.P., et al. A Single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS ONE 2016, 11, e0149871.
34. Bodilis, H.C., Benabdelmoumen, G., Gergely, A., Goujon, C., Pelicot, M., Poujol, P., Consigny, P.H. Persistance à long terme des anticorps neutralisants de la fièvre jaune chez les personnes âgées de 60 ans et plus. Bull. Soc. Pathol. Exot. 2011, 104, 260–265.
35. Hepburn, M.J., Kortepeter, M.G., Pittman, P.R., Boudreau, E.F., Mangiafico, J.A., Buck, P.A., Norris, S.L., Anderson, E.L. Neutralizing antibody response to booster vaccination with the 17D yellow fever vaccine. Vaccine 2006, 24, 2843–2849.
36. Da Costa Neves, P.C., de Souza Matos, D.C., Marcovistz, R., Galler, R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 2009, 27, 5543–5549.
37. Gaucher, D., Therrien, R., Kettaf, N., Angermann, B.R., Boucher, G., Filali-Mouhim, A., Moser, J.M., Mehta, R.S., Drake, D.R., Castro, E., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 2008, 205, 3119–3131.
38. Luiza-Silva, M., Campi-Azevedo, A.C., Batista, M.A., Martins, M.A., Avelar, R.S., da Silveira Lemos, D., Bastos Camacho, L.A., de Menezes Martins, R., de Lourdes de Sousa Maia, M., Guedes Farias, R.H., et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. J. Infect. Dis. 2011, 204, 873–883.
39. Silva, M.L., Martins, M.A., Espírito-Santo, L.R., Campi-Azevedo, A.C., Silveira-Lemos, D., Ribeiro, J.G.L., Homma, A., Kroon, E.G., Teixeira-Carvalho, A., Elói-Santos, S.M., et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011, 29, 583–592.
40. Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009, 10, 116–125.
41. Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., Pulendran, B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203, 413–424.
42. Palmer, D.R., Fernandez, S., Bisbing, J., Peachman, K.K., Rao, M., Barvir, D., Gunther, V., Burgess, T., Kohno, Y., Padmanabhan, R., et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J. Gen. Virol. 2007, 88, 148–156.
43. Barba-Spaeth, G., Longman, R.S., Albert, M.L., Rice, C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 2005, 202, 1179–1184.
44. Akondy, R.S., Johnson, P.L.F., Nakaya, H.I., Edupuganti, S., Mulligan, M.J., Lawson, B., Miller, J.D., Pulendran, B., Antia, R., Ahmed, R. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc. Natl. Acad. Sci. USA 2015, 112, 3050–3055.
45. Kohler, S., Bethke, N., Böthe, M., Sommerick, S., Frentsch, M., Romagnani, C., Niedrig, M., Thiel, A. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 2012, 42, 2363–2373.
46. Blom, K., Braun, M., Ivarsson, M.A., Gonzalez, V.D., Falconer, K., Moll, M., Ljunggren, H.-G., Michaëlsson, J., Sandberg, J.K. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J. Immunol. 2013, 190, 2150–2158.
47. James, E.A., LaFond, R.E., Gates, T.J., Mai, D.T., Malhotra, U., Kwok, W.W. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J. Virol. 2013, 87, 12794–12804.
48. Martins, M.A., Silva, M.L., Marciano, A.P.V., Peruhype-Magalhães, V., Eloi-Santos, S.M., Ribeiro, J.G.L., Correa-Oliveira, R., Homma, A., Kroon, E.G., Teixeira-Carvalho, A., et al. Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: Is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol. 2007, 148, 90–100.
49. Miller, J.D., van der Most, R.G., Akondy, R.S., Glidewell, J.T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P.L., Edupuganti, S., Lalor, S., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28, 710–722.
50. Akondy, R.S., Monson, N.D., Miller, J.D., Edupuganti, S., Teuwen, D., Wu, H., Quyyumi, F., Garg, S., Altman, J.D., Del Rio, C., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 2009, 183, 7919–7930.
51. DeWitt, W. S., Emerson, R. O., Lindau, P., Vignali, M., Snyder, T. M., Desmarais, C., Sanders, C., Utsugi, H., Warren, E. H., McElrath, J., Makar, K. W., Wald, A., Robins, H. S. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 2015, 89, 4517–4526.
52. Marraco, S.A.F., Soneson, C., Cagnon, L., Gannon, P.O., Allard, M., Maillard, S.A., Montandon, N., Rufer, N., Waldvogel, S., Delorenzi, M., et al. Long-lasting stem cell–like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination. Sci. Transl. Med. 2015, 7, 282ra48.
53. Campi-Azevedo, A.C., Araújo-Porto, L.P.D., Luiza-Silva, M., Batista, M.A., Martins, M.A., Sathler-Avelar, R., da Silveira-Lemos, D., Camacho, L.A.B., de Menezes Martins, R., de Lourdes de Sousa Maia, M., et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS ONE 2012, 7, e49828.
54. Crotty, S. Follicular helper CD4 T cells (TFH). Ann. Rev. Immunol. 2011, 29, 621–663.
55. Swain, S.L., McKinstry, K.K., Strutt, T.M. Expanding roles for CD4+ T cells in immunity to viruses. Nat. Rev. Immunol. 2012, 12, 136–148.
56. Bassi, M.R., Kongsgaard, M., Steffensen, M.A., Fenger, C., Rasmussen, M., Skjodt, K., Finsen, B., Stryhn, A., Buus, S., Christensen, J.P., et al. CD8+ T cells complement antibodies in protecting against yellow fever virus. J. Immunol. 2015, 194, 1141–1153.
57. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M., Koup, R.A. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 2003, 281, 65–78.
58. Ter Meulen, J., Sakho, M., Koulemou, K., Magassouba, N., Bah, A., Preiser, W., Daffis, S., Klewitz, C., Bae, H.-G., Niedrig, M., et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J. Infect. Dis. 2004, 190, 1821–1827.
59. Quaresma, J.A.S., Barros, V.L.R.S., Pagliari, C., Fernandes, E.R., Guedes, F., Takakura, C.F.H., Andrade, H.F., Jr., Vasconcelos, P.F.C., Duarte, M.I.S. Revisiting the liver in human yellow fever: Virus-induced apoptosis in hepatocytes associated with TGF-β, TNF-α and NK cells activity. Virology 2006, 345, 22–30.
60. Quaresma, J.A.S., Barros, V.L.R.S., Pagliari, C., Fernandes, E.R., Andrade, H.F., Jr., Vasconcelos, P.F.C., Duarte, M.I.S. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans. R. Soc. Trop. Med. Hyg. 2007, 101, 161–168.
61. Quaresma, J.A.S., Duarte, M.I.S., Vasconcelos, P.F.C. Midzonal lesions in yellow fever: A specific pattern of liver injury caused by direct virus action and in situ inflammatory response. Med. Hypotheses 2006, 67, 618–621.
62. Mason, R.A., Tauraso, N.M., Spertzel, R.O., Ginn, R.K. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 1973, 25, 539–544.
63. Bonaldo, M.C., Martins, M.A., Rudersdorf, R., Mudd, P.A., Sacha, J.B., Piaskowski, S.M., Neves, P.C.C., Santana, M.G.V.D., Vojnov, L., Capuano, S., et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 Gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J. Virol. 2010, 84, 3699–3706.
64. Mudd, P.A., Piaskowski, S.M., Neves, P.C.C., Rudersdorf, R., Kolar, H.L., Eernisse, C.M., Weisgrau, K.L., de Santana, M.G.V., Wilson, N.A., Bonaldo, M.C., et al. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques— Implications for recombinant vaccine design. Immunogenetics 2010, 62, 593–600.
65. Neves, P.C.C., Rudersdorf, R.A., Galler, R., Bonaldo, M.C., de Santana, M.G.V., Mudd, P.A., Martins, M.A., Rakasz, E.G., Wilson, N.A., Watkins, D.I. CD8+ γ+ TCR+ and CD4+ T cells produce IFN-γ at 5–7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 2010, 28, 8183–8188.
66. Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., Ryman, K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009, 5, e1000614.
67. Watson, A.M., Lam, L.K.M., Klimstra, W.B., Ryman, K.D. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells. PLoS Pathog. 2016, 12, e1005786.
68. Liu, T., Chambers, T.J. Yellow fever virus encephalitis: Properties of the brain-associated T-cell response during virus clearance in normal and γ interferon-deficient mice and requirement for CD4+ lymphocytes. J. Virol. 2001, 75, 2107–2118.
69. Vandermost, R., Harrington, L., Giuggio, V., Mahar, P., Ahmed, R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 2002, 296, 117–124.
70. Bassi, M.R., Larsen, M.A.B., Kongsgaard, M., Rasmussen, M., Buus, S., Stryhn, A., Thomsen, A.R., Christensen, J.P. Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice. PLoS Negl. Trop. Dis. 2016, 10, e0004464.
71. Barrett, A.D.T., Gould, E.A. Comparison of neurovirulence of different strains of yellow fever virus in mice. J. Gen. Virol. 1986, 67, 631–637.
72. Watson, A.M., Lam, L.K.M., Klimstra, W.B. CD8+ T cells are Required for the Control of the Live Attenuated 17D-204 Yellow Fever Vaccine. Manuscript under preparation.
73. Haring, J.S., Badovinac, V.P., Harty, J.T. Inflaming the CD8+ T cell response. Immunity 2006, 25, 19–29.
74. Thompson, L.J., Kolumam, G.A., Thomas, S., Murali-Krishna, K. Innate inflammatory signals induced by various pathogens ddifferentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 2006, 177, 1746–1754.
75. Deauvieau, F., Sanchez, V., Balas, C., Kennel, A., De Montfort, A., Lang, J., Guy, B. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1–4. Am. J. Trop. Med. Hyg. 2007, 76, 144–154.
76. Gandini, M., Reis, S.R.N.I., Torrentes-Carvalho, A., Azeredo, E.L., Freire, M.D.S., Galler, R., Kubelka, C.F. dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles. Memórias do Instituto Oswaldo Cruz 2011, 106, 594–605.
77. Mandl, J.N., Akondy, R., Lawson, B., Kozyr, N., Staprans, S.I., Ahmed, R., Feinberg, M.B. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J. Immunol. 2011, 186, 6406–6416.
78. Bruni, D., Chazal, M., Sinigaglia, L., Chauveau, L., Schwartz, O., Desprès, P., Jouvenet, N. Viral entry route determines how human plasmacytoid dendritic cells produce type I interferons. Sci. Signal. 2015, 8, ra25.
79. Thibodeaux, B. A., Garbino, N. C., Liss, N. M., Piper, J., Blair, C. D., Roehrig, J. T. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 2012, 30, 3180–3187.
80. Chen, K., Liu, J., Cao, X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. Journal of Autoimmunity.
81. Ramana, C. V., Gil, M. P., Schreiber, R. D., Stark, G. R. STAT1-dependent and -independent pathways in IFN-γ-dependent signaling. Trends in Immunology 2002, 23, 96–101.
82. Douam, F., Hrebikova, G., Albrecht, Y. E. S., Sellau, J., Sharon, Y., Ding, Q., Ploss, A. Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome. Nature Communications 2017, 8, 14781.
83. Greene, J.M., Burwitz, B.J., Blasky, A.J., Mattila, T.L., Hong, J.J., Rakasz, E.G., Wiseman, R.W., Hasenkrug, K.J., Skinner, P.J., O’Connor, S.L., et al. Allogeneic lymphocytes persist and traffic in feral MHC-matched Mauritian cynomolgus macaques. PLoS ONE 2008, 3, e2384.
84. Ross, C.N., French, J.A., Ortí, G. Germ-line chimerism and paternal care in marmosets (Callithrix kuhlii). Proc. Natl. Acad. Sci. USA 2007, 104, 6278–6282.